Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance

Abbott LaboratoriesTrade
Vanguard Intermediate Term Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Abbott Laboratories trades at $109.12 (market cap $187.95B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

ABTVCIT
Market Cap
$187.95B
Sector
HealthFixed Income
52-Week High
$136.62$84.82
52-Week Low
$82.57$81.07
Enterprise Value
$214.96B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

Vanguard Intermediate Term Corporate Bond ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Vanguard Intermediate Term Corporate Bond ETF

VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.

Read more on VCIT